Intrahepatic cholangiocarcinoma: current perspectives.

Area of Science:

• Hepatobiliary Malignancies
• Gastrointestinal Oncology
• Translational Cancer Research

Background:

• Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver malignancy, accounting for 10% of all cholangiocarcinomas.
• Histologically, ICC predominantly presents as adenocarcinoma arising from intrahepatic bile ducts.
• Resectable disease is rare (15%), with a median survival under 3 years, highlighting the need for improved management strategies.

Purpose of the Study:

• To review current challenges and advancements in the multidisciplinary management of intrahepatic cholangiocarcinoma.
• To emphasize the need for accurate predictive risk factors for patient selection in systemic therapies.
• To discuss the potential of molecular markers and novel treatment strategies for locally advanced ICC.

Main Methods:

• Review of existing literature on intrahepatic cholangiocarcinoma epidemiology, pathology, and treatment.
• Analysis of risk models and nomograms for survival prediction.
• Evaluation of emerging systemic treatments and locoregional therapies.

Main Results:

• Multidisciplinary management is complex due to variable disease courses.
• Existing risk models aim for improved survival prediction based on clinical parameters.
• Molecular markers like EGFR status show promise but require clinical validation.
• Locoregional therapies (e.g., hepatic arterial infusion chemotherapy, Yttrium-90 embolization) are being evaluated for downstaging locally advanced ICC.

Conclusions:

• Accurate risk stratification and validated molecular markers are crucial for optimizing intrahepatic cholangiocarcinoma treatment.
• Downstaging therapies offer potential benefits for selected patients with locally advanced disease, aiming to improve resectability or delay progression.
• Further research is needed to integrate molecular insights and advanced therapies into clinical practice for better patient outcomes.